BLPH stock forecast
Our latest prediction for Bellerophon Therapeutics, Inc.'s stock price was made on the Nov. 25, 2019 when the stock price was at 0.38$.
In the short term (2weeks), BLPH's stock price should outperform the market by 7.55%. During that period the price should oscillate between -10.49% and +22.60%.
In the medium term (3months), BLPH's stock price should outperform the market by 24.94%. During that period the price should oscillate between -26.29% and +51.59%.Get email alerts
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.21$ per share.
The book value per share is -0.13$
Three months stock forecastNov. 25, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|